FLT3LG and neoplasm: Importantly, most immunotherapies fail completely in the absence of cross-presenting DC [44,46], which are sparse in many types of tumors, and we and others have shown in preclinical studies that induction of cDC1 at the tumor site using Flt3L can induce response to checkpoint inhibitors in previously unresponsive tumors [30,33].